Dergiler / Türk Tarım ve Doğa Bilimleri Dergisi / 2026 / Volume: 13 Issue: 1

Production, Purification, and Initial Crystallization of Recombinant Epidermal Growth Factor Receptor Tyrosine Kinase Domain (EGFR-TKD) as a Structural Basis for Future Drug Screening Studies

Edanur Topalan(KOC UNIVERSITY, FACULTY OF SCIENCE)0009-0009-0532-020X
Halilibrahim Çiftçi(BURDUR MEHMET AKİF ERSOY UNIVERSITY)0000-0002-9796-7669
Hasan Demirci(KOÇ ÜNİVERSİTESİ, FEN FAKÜLTESİ)0000-0002-9135-5397
Sayfa
—
Yayın Tarihi
2026-01-22
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Overall, the workflow establishes a practical and reproducible bacterial expression and purification strategy that forms a basis for continued crystallization optimization and structure-based inhibitor development targeting EGFR-driven cancers.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The epidermal growth factor receptor tyrosine kinase domain (EGFR-TKD) is a key regulator of intracellular signaling events that control cell proliferation.
📊
Temel Bulgular & Veri:In this study, recombinant EGFR-TKD was expressed in Escherichia coli Rosetta™ 2 (DE3) cells using a pET28a(+) expression plasmid carrying an N-terminal 6×His-SUMO- tag.
💡
Sonuç & Katkı:Overall, the workflow establishes a practical and reproducible bacterial expression and purification strategy that forms a basis for continued crystallization optimization and structure-based inhibitor development targeting EGFR-driven cancers.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:EGFR · recombinant protein · sarcosyl

Abstract

The epidermal growth factor receptor tyrosine kinase domain (EGFR-TKD) is a key regulator of intracellular signaling events that control cell proliferation. Aberrant EGFR activation is closely associated with the development of non-small cell lung cancer (NSCLC). In this study, recombinant EGFR-TKD was expressed in Escherichia coli Rosetta™ 2 (DE3) cells using a pET28a(+) expression plasmid carrying an N-terminal 6×His-SUMO- tag. During expression, a large proportion of the protein accumulated in inclusion bodies; therefore, we employed a solubilization approach. Treatment with 1.5% sarcosyl reproducibly yielded a soluble protein fraction compatible with subsequent purification steps. Optimizing induction parameters, including temperature, IPTG concentration, and expression duration, improved both the yield and solubility of the protein. Following size-exclusion chromatography, the monomeric protein fraction was isolated and used for crystallization trials, which resulted in the formation of small but well-defined microcrystals under several conditions. Although these crystals did not yet provide diffraction suitable for structure determination, their reproducible appearance indicates that the obtained EGFR-TKD is structurally competent for crystallization trials. Overall, the workflow establishes a practical and reproducible bacterial expression and purification strategy that forms a basis for continued crystallization optimization and structure-based inhibitor development targeting EGFR-driven cancers.

🔖

Bu Makaleye Atıf Yap

Topalan, E., Çiftçi, H., Demirci, H. (2026). Production, Purification, and Initial Crystallization of Recombinant Epidermal Growth Factor Receptor Tyrosine Kinase Domain (EGFR-TKD) as a Structural Basis for Future Drug Screening Studies. Türk Tarım ve Doğa Bilimleri Dergisi, Volume: 13 Issue: 1. https://doi.org/10.30910/turkjans.1805082

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (35)

  1. Atalay, N., Akcan, E. K., Gül, M., Ayan, E., Destan, E., Ertem, F. B., Tokay, N., Çakilkaya, B., Nergiz, Z., Karakadioğlu, G., Kepceoğlu, A., Yapici, İ., Tosun, B., Baldir, N., Yildirim, G., Johnson, J. A., Güven, Ö., Shafiei, A., Arslan, N. E.,. Demirci, H. (2023). Cryogenic X-ray crystallographic studies of biomacromolecules at Turkish Light Source "Turkish DeLight". Turkish Journal of Biology, 47(1), 1–13. https://doi.org/10.55730/1300-0152.2637
  2. Brazel, D., Kroening, G., & Nagasaka, M. (2022). Non‐small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: Diagnosis and treatment options. BioDrugs, 36(6), 717–729. https://doi.org/10.1007/s40259-022-00556-4
  3. Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Dias, J. M., Besse, B., Lee, K.-H., Xiong, H., How, S.-H., Cheng, Y., Chang, G.-C., Yoshioka, H.,. Hayashi, H. (2024). Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC. The New England Journal of Medicine, 391(16), 1486–1498. https://doi.org/10.1056/NEJMoa2403614
  4. Çiftçi, H., Otsuka, M., Fujita, M., & Sever, B. (2024). New naphthalene-linked pyrazoline–thiazole hybrids as prominent antilung and anti-breast cancer inhibitors. Turkish Journal of Chemistry, 48(6), 856–866. https://doi.org/10.55730/1300-0527.3704
  5. Das, D., Wang, J., & Hong, J. (2021). Next‐generation kinase inhibitors targeting specific biomarkers in non‐small cell lung cancer (NSCLC): A recent overview. ChemMedChem, 16(16), 2459–2479. https://doi.org/10.1002/cmdc.202100166
  6. Das, D., Xie, L., & Hong, J. (2024). Next‐generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non‐small cell lung cancer (2019–2024). RSC Medicinal Chemistry, 15(10), 3371–3394. https://doi.org/10.1039/d4md00384e
  7. Eck, M. J., & Yun, C. H. (2010). Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non‐small cell lung cancer. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1804(3), 559–566. https://doi.org/10.1016/j.bbapap.2009.12.010
  8. Elloumi-Mseddi, J., Jellali, K., & Aifa, S. (2013). In vitro activation and inhibition of recombinant EGFR tyrosine kinase expressed in Escherichia coli. The Scientific World Journal, 2013, 807284. https://doi.org/10.1155/2013/807284
  9. Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H. S., Leahy, D. J., & Lemmon, M. A. (2003). EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Molecular Cell, 11(2), 507–517. https://doi.org/10.1016/s1097-2765(03)00047-9
  10. Frezzetti, D., Caridi, V., Marra, L., et al. (2024). The impact of inadequate exposure to epidermal growth factor receptor‐tyrosine kinase inhibitors on the development of resistance in non‐small‐cell lung cancer cells. International Journal of Molecular Sciences, 25(9), 4844. https://doi.org/10.3390/ijms25094844
  11. Gou, Q., Gan, X., & Xie, Y. (2024). Novel therapeutic strategies for rare mutations in non‐small cell lung cancer. Scientific Reports, 14(1), 10317. https://doi.org/10.1038/s41598-024-61087-2
  12. Harris, R. C., Chung, E., & Coffey, R. J. (2003). EGF receptor ligands. Experimental Cell Research, 284(1), 2–13. https://doi.org/10.1016/s0014-4827(02)00105-2
  13. Hubbard, S. R. (1999). Structural analysis of receptor tyrosine kinases. Progress in Biophysics and Molecular Biology, 71(3–4), 343–358. https://doi.org/10.1016/s0079-6107(98)00047-9
  14. Janmaat, M. L., Kruyt, F. A., Rodriguez, J. A., & Giaccone, G. (2003). Response to epidermal growth factor receptor inhibitors in non‐small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal‐regulated kinase or Akt kinase pathways. Clinical Cancer Research, 9(6), 2316–2326.
  15. Johnson, M., Garassino, M. C., Mok, T., & Mitsudomi, T. (2022). Treatment strategies and outcomes for patients with EGFR‐mutant non‐small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Lung Cancer, 170, 41–51. https://doi.org/10.1016/j.lungcan.2022.05.011
  16. Jura, N., Endres, N. F., Engel, K., et al. (2009). Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell, 137(7), 1293–1307. https://doi.org/10.1016/j.cell.2009.04.025
  17. Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 1117–1134. https://doi.org/10.1016/j.cell.2010.06.011
  18. Lenferink, A. E. G. (1998). Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO Journal, 17(12), 3385–3397. https://doi.org/10.1093/emboj/17.12.3385
  19. Mansour, M. A., AboulMagd, A. M., Abbas, S. H., Abdel‐Rahman, H. M., & Abdel‐Aziz, M. (2023). Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non‐small cell lung cancer resistance: A critical review. RSC Advances, 13(27), 18825–18853. https://doi.org/10.1039/d3ra02347h
  20. Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016). Mechanisms of resistance to EGFR‐targeted drugs: Lung cancer. ESMO Open, 1(3), e000060. https://doi.org/10.1136/esmoopen-2016-000060
  21. Niggenaber, J., Hardick, J., Lategahn, J., & Rauh, D. (2020). Structure defines function: Clinically relevant mutations in ErbB kinases. Journal of Medicinal Chemistry, 63(1), 40–51. https://doi.org/10.1021/acs.jmedchem.9b00964
  22. Oxnard, G. R., Lo, P. C., Nishino, M., et al. (2013). Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. Journal of Thoracic Oncology, 8(2), 179–184. https://doi.org/10.1097/JTO.0b013e3182779d18
  23. Reymova, F., Sever, B., Topalan, E., et al. (2025). Design, synthesis, and mechanistic anticancer evaluation of new pyrimidine‐tethered compounds. Pharmaceuticals, 18(2), 270. https://doi.org/10.3390/ph18020270
  24. Roskoski, R., Jr. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 79, 34–74. https://doi.org/10.1016/j.phrs.2013.11.002
  25. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27. PMID: 30500458.
  26. Sever, B., Altıntop, M. D., Radwan, M. O., et al. (2019). Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. European Journal of Medicinal Chemistry, 182, 111648. https://doi.org/10.1016/j.ejmech.2019.111648
  27. Sever, B., Otsuka, M., Fujita, M., Ciftci, H. (2025) Design, Synthesis, and Anticancer Evaluation of New Small-Molecule EGFR Inhibitors Targeting NSCLC and Breast Cancer. International Journal of Molecular Sciences, 26(15), 7065. https://doi.org/10.3390/ijms26157065
  28. Topalan, E., Büyükgüngör, A., Çiğdem, M., Güra, S., Sever, B., Otsuka, M., Fujita, M., Demirci, H., & Çiftci, H. (2025). A structural insight into two important ErbB receptors (EGFR and HER2) and their relevance to non-small cell lung cancer. Archiv der Pharmazie, 358, e2400992. https://doi.org/10.1002/ardp.202400992
  29. Wang, K., Fu, Z., Sun, G., et al. (2024). Systemic treatment options for non‐small cell lung cancer after failure of previous immune checkpoint inhibitors: A Bayesian network meta‐analysis based on randomized controlled trials. BMC Immunology, 25(1), 37. https://doi.org/10.1186/s12865-024-00633-z
  30. Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018). Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annals of Oncology, 29(Suppl 1), i10–i19. https://doi.org/10.1093/annonc/mdx703
  31. Yarden, Y., & Pines, G. (2012). The ERBB network: At last, cancer therapy meets systems biology. Nature Reviews Cancer, 12(8), 553–563. https://doi.org/10.1038/nrc3309
  32. Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127–137. https://doi.org/10.1038/35052073
  33. Zhao, Y., Wang, H., & He, C. (2021). Drug resistance of targeted therapy for advanced non‐small cell lung cancer harbored EGFR mutation: From mechanism analysis to clinical strategy. Journal of Cancer Research and Clinical Oncology, 147(12), 3653–3664. https://doi.org/10.1007/s00432-021-03828-8
  34. Atalay, N., Akcan, E. K., Gül, M., Ayan, E., Destan, E., Ertem, F. B., Tokay, N., Çakilkaya, B., Nergiz, Z., Karakadioğlu, G., Kepceoğlu, A., Yapici, İ., Tosun, B., Baldir, N., Yildirim, G., Johnson, J. A., Güven, Ö., Shafiei, A., Arslan, N. E.,. Demirci, H. (2023). Cryogenic X-ray crystallographic studies of biomacromolecules at Turkish Light Source "Turkish DeLight". Turkish Journal of Biology, 47(1), 1–13. https://doi.org/10.55730/1300-0152.2637
  35. Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Dias, J. M., Besse, B., Lee, K.-H., Xiong, H., How, S.-H., Cheng, Y., Chang, G.-C., Yoshioka, H.,. Hayashi, H. (2024). Amivantamab plus Lazertinib in previously untreated EGFR-mutated advanced NSCLC. The New England Journal of Medicine, 391(16), 1486–1498. https://doi.org/10.1056/NEJMoa2403614